<p>/PRNewswire/ -- Aethlon Medical, Inc.（“Aethlon” 或 “公司”）（纳斯达克：AEMD）是一家专注于开发治疗癌症和危及生命的传染病产品的医疗治疗公司，今天宣布已与单一机构投资者签署了一项证券购买协议，购买 595,897 股普通股（或预先融资的认股权证），以及可购买最多 1,042,820 股普通股的认股权证，进行一项根据纳斯达克规则按市场价格定价的私募。每股普通股（或预先融资的认股权证）及其附带认股权证的综合有效发行价格为 4.03 美元。认股权证的行使价格为每股 4.03 美元，需经股东批准后方可行使，并将在股东批准之日起五年半后到期。</p>
<p>公司还与投资者签署了一项认股权证诱导协议，以行使公司在 2025 年 3 月（“2025 年 3 月认股权证”）和 2025 年 9 月（“2025 年 9 月认股权证”）分别发行的某些未行使认股权证。根据认股权证诱导协议，投资者同意将未行使的 2025 年 3 月认股权证和 2025 年 9 月认股权证的行使价格降低至修订后的 4.03 美元，并行使未行使的 2025 年 3 月认股权证购买公司普通股的总计 155,000 股，以及未行使的 2025 年 9 月认股权证购买公司普通股的总计 55,555 股，行使价格为修订后的 4.03 美元。作为对立即行使 2025 年 3 月认股权证和 2025 年 9 月认股权证的对价，公司还同意向投资者发行未注册的认股权证，以购买公司普通股的总计 368,471 股（“新认股权证”）。新认股权证的行使价格为每股 4.03 美元，需经股东批准后方可行使，并将在股东批准之日起五年半后到期。</p>
<p>公司从私募和认股权证诱导中获得的总收入预计约为 330 万美元，未扣除承销商费用和其他预计的发行费用。该发行预计将在 2025 年 12 月 8 日左右完成，前提是满足惯例的交割条件。</p>
<p>Maxim Group LLC 作为此次发行的唯一承销商。</p>
<p>上述证券的发行和销售是在 1933 年证券法（“证券法”）第 4(a)(2) 条及其下颁布的 D 条款的私募中进行的，且这些证券未在证券法或适用的州证券法下注册。因此，除非根据有效的注册声明或适用的证券法注册要求的豁免，否则这些证券不得在美国转售或再提供。公司已同意向证券交易委员会提交注册声明，以注册在私募和认股权证诱导中发行的证券的转售。</p>
<p>本新闻稿不构成出售证券的要约或购买证券的邀请，也不应在任何州进行证券的销售，除非在该州的证券法下注册或资格之前，该要约、邀请或销售是非法的。根据转售注册声明的任何证券发行仅通过招股说明书进行。</p>
<p><strong>关于 Aethlon Medical, Inc.</strong></p>
<p>Aethlon Medical, Inc.（纳斯达克：AEMD）是一家总部位于加利福尼亚州圣地亚哥的临床阶段医疗设备公司。Aethlon 正在推进 Hemopurifier，以满足肿瘤学和传染病领域的未满足需求，使用一种新颖的平台，旨在选择性去除生物液体中的循环病原体目标。</p>
<p>欲了解更多信息，请访问 www.AethlonMedical.com 并在 LinkedIn 上关注公司。</p>
<p><strong>前瞻性声明</strong></p>
<p>本新闻稿包含根据 1933 年证券法第 27A 条和 1934 年证券交易法第 21E 条的定义的前瞻性声明，这些声明涉及风险和不确定性。包含 “可能”、“相信”、“预期”、“期待”、“打算”、“计划”、“项目”、“将”、“预测”、“估计”、“潜在” 或类似表达的声明构成前瞻性声明。这些前瞻性声明受到重大风险和不确定性的影响，实际结果可能与前瞻性声明中预期的结果有重大差异。这些前瞻性声明基于 Aethlon 当前的预期，并涉及可能永远无法实现或可能被证明不正确的假设。可能导致这些差异的因素包括但不限于：公司筹集额外资本的能力、维持其纳斯达克上市的能力、成功完成 Hemopurifier 的开发的能力；公司成功展示 Hemopurifier 在癌症和传染病以及移植环境中的效用的能力；Hemopurifier 在相当于 4 小时 HP 治疗的时间点继续显示去除血小板衍生 EVs 的能力；公司实现和实现其潜在里程碑的预期收益的能力；公司向澳大利亚和印度的额外伦理委员会提交申请并获得批准的能力，包括公司预期的时间；公司在澳大利亚和印度启动和继续其计划中的肿瘤临床试验的能力，包括公司预期的时间；公司管理和成功完成其临床试验（如果启动）的能力；公司成功制造足够数量的 Hemopurifier 以供其临床试验的能力，以及其他潜在风险。上述风险和不确定性清单仅为示例，并非详尽无遗。可能导致结果与前瞻性声明中预期的结果有重大差异的其他因素可以在公司截至 2025 年 3 月 31 日的 10-K 表格年度报告中的 “风险因素” 标题下找到，以及公司向证券交易委员会提交的其他文件，包括其 10-Q 表格的季度报告。本新闻稿中包含的所有前瞻性声明仅在作出声明的日期有效。除非法律要求，否则公司不打算也不承担任何更新此信息以反映未来事件或情况的义务。</p>
<p><strong>公司联系人：</strong> Jim Frakes</p>
<p>首席执行官兼首席财务官</p>
<p>Aethlon Medical, Inc.</p>
<p>Jfrakes@aethlonmedical.com</p>
<p><strong>投资者联系人：</strong> Susan Noonan</p>
<p>S.A. Noonan Communications, LLC</p>
<p>susan@sanoonan.com</p>
<p>917-513-5303</p>
<p>来源：Aethlon Medical, Inc.</p>

AEMD

<p>Aethlon Medical, Inc. 宣布与一位机构投资者达成了一项 330 万美元的私募协议，涉及普通股和认股权证的购买。该发行价格符合纳斯达克规则的市场价格，认股权证需经股东批准后方可行使。公司还签署了一项认股权证诱导协议，以修改现有认股权证的行使价格。该发行预计将在 2025 年 12 月 8 日之前完成，Maxim Group LLC 担任配售代理。该证券以私募方式发行，未在证券法下注册</p>

<p>, /PRNewswire/ -- Aethlon Medical, Inc. (&#34;Aethlon&#34; or the &#34;Company&#34;) (Nasdaq: AEMD), a medical therapeutic company focused on developing products to treat cancer and life-threatening infectious diseases, today announced that it has entered into a securities purchase agreement with a single institutional investor to purchase 595,897 shares of common stock (or pre-funded warrants in-lieu thereof), together with warrants to purchase up to an aggregate 1,042,820 shares of common stock, in a private placement priced at-the-market under Nasdaq rules. The combined effective offering price for each share of common stock (or pre-funded warrant in-lieu thereof) and accompanying warrants is $4.03. The warrants will have an exercise price of $4.03 per share, will be exercisable upon shareholder approval, and will expire on the five and one-half year anniversary from such date of shareholder approval.</p>
<div class="lb-trans"><p>/PRNewswire/ -- Aethlon Medical, Inc.（“Aethlon” 或 “公司”）（纳斯达克：AEMD）是一家专注于开发治疗癌症和危及生命的传染病产品的医疗治疗公司，今天宣布已与单一机构投资者签署了一项证券购买协议，购买 595,897 股普通股（或预先融资的认股权证），以及可购买最多 1,042,820 股普通股的认股权证，进行一项根据纳斯达克规则按市场价格定价的私募。每股普通股（或预先融资的认股权证）及其附带认股权证的综合有效发行价格为 4.03 美元。认股权证的行使价格为每股 4.03 美元，需经股东批准后方可行使，并将在股东批准之日起五年半后到期。</p>
</div><p>The Company has also entered into a warrant inducement agreement with the investor to exercise certain outstanding warrants that the Company issued in March 2025 (the &#34;March 2025 Warrants&#34;) and September 2025 (the &#34;September 2025 Warrants&#34;), respectively. Pursuant to a warrant inducement agreement, the investor has agreed to a reduced exercise price of the outstanding March 2025 Warrants and September 2025 Warrants to an amended exercise price of $4.03, and to exercise the outstanding March 2025 Warrants to purchase an aggregate of 155,000 shares of the Company's common stock and the outstanding September 2025 Warrants to purchase an aggregate of 55,555 shares of the Company's common stock, at the amended exercise price of $4.03. In consideration for the immediate exercise of the March 2025 Warrants and September 2025 Warrants, the Company also agreed to issue the investor unregistered warrants to purchase an aggregate of 368,471 shares of the Company's common stock (the &#34;New Warrants&#34;). The New Warrants will have an exercise price of $4.03 per share, will be exercisable upon shareholder approval, and will expire on the five and one-half year anniversary from such date of shareholder approval.</p>
<div class="lb-trans"><p>公司还与投资者签署了一项认股权证诱导协议，以行使公司在 2025 年 3 月（“2025 年 3 月认股权证”）和 2025 年 9 月（“2025 年 9 月认股权证”）分别发行的某些未行使认股权证。根据认股权证诱导协议，投资者同意将未行使的 2025 年 3 月认股权证和 2025 年 9 月认股权证的行使价格降低至修订后的 4.03 美元，并行使未行使的 2025 年 3 月认股权证购买公司普通股的总计 155,000 股，以及未行使的 2025 年 9 月认股权证购买公司普通股的总计 55,555 股，行使价格为修订后的 4.03 美元。作为对立即行使 2025 年 3 月认股权证和 2025 年 9 月认股权证的对价，公司还同意向投资者发行未注册的认股权证，以购买公司普通股的总计 368,471 股（“新认股权证”）。新认股权证的行使价格为每股 4.03 美元，需经股东批准后方可行使，并将在股东批准之日起五年半后到期。</p>
</div><p>The gross proceeds to the Company from the private placement and warrant inducement are estimated to be approximately $3.3 million before deducting the placement agent's fees and other estimated offering expenses. The offering is expected to close on or about December 8, 2025, subject to the satisfaction of customary closing conditions.</p>
<div class="lb-trans"><p>公司从私募和认股权证诱导中获得的总收入预计约为 330 万美元，未扣除承销商费用和其他预计的发行费用。该发行预计将在 2025 年 12 月 8 日左右完成，前提是满足惯例的交割条件。</p>
</div><p>Maxim Group LLC is acting as the sole placement agent in connection with the offering.</p>
<div class="lb-trans"><p>Maxim Group LLC 作为此次发行的唯一承销商。</p>
</div><p>The offer and sale of the foregoing securities are being made in a private placement under Section 4(a)(2) of the Securities Act of 1933, as amended (the &#34;Securities Act&#34;), and/or Regulation D promulgated thereunder, and the securities have not been registered under the Securities Act or applicable state securities laws. Accordingly, the securities may not be reoffered or resold in the United States except pursuant to an effective registration statement or an applicable exemption from the registration requirements of the Securities Act and such applicable state securities laws. The Company has agreed to file a registration statement with the Securities and Exchange Commission registering the resale of the securities issued in the private placement and warrant inducement.</p>
<div class="lb-trans"><p>上述证券的发行和销售是在 1933 年证券法（“证券法”）第 4(a)(2) 条及其下颁布的 D 条款的私募中进行的，且这些证券未在证券法或适用的州证券法下注册。因此，除非根据有效的注册声明或适用的证券法注册要求的豁免，否则这些证券不得在美国转售或再提供。公司已同意向证券交易委员会提交注册声明，以注册在私募和认股权证诱导中发行的证券的转售。</p>
</div><p>This press release does not constitute an offer to sell or the solicitation of an offer to buy the securities, nor shall there be any sale of the securities in any state in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of such state. Any offering of the securities under the resale registration statement will only be made by means of a prospectus.</p>
<div class="lb-trans"><p>本新闻稿不构成出售证券的要约或购买证券的邀请，也不应在任何州进行证券的销售，除非在该州的证券法下注册或资格之前，该要约、邀请或销售是非法的。根据转售注册声明的任何证券发行仅通过招股说明书进行。</p>
</div><p><strong>About Aethlon Medical, Inc.</strong></p>
<div class="lb-trans"><p><strong>关于 Aethlon Medical, Inc.</strong></p>
</div><p>Aethlon Medical, Inc. (Nasdaq: AEMD) is a clinical-stage medical device company headquartered in San Diego, California. Aethlon is advancing the Hemopurifier, to address unmet needs in oncology and infectious disease, using a novel platform designed to selectively remove circulation pathogenic targets from biologic fluids.</p>
<div class="lb-trans"><p>Aethlon Medical, Inc.（纳斯达克：AEMD）是一家总部位于加利福尼亚州圣地亚哥的临床阶段医疗设备公司。Aethlon 正在推进 Hemopurifier，以满足肿瘤学和传染病领域的未满足需求，使用一种新颖的平台，旨在选择性去除生物液体中的循环病原体目标。</p>
</div><p>For more information, visit www.AethlonMedical.com and follow the Company on LinkedIn.</p>
<div class="lb-trans"><p>欲了解更多信息，请访问 www.AethlonMedical.com 并在 LinkedIn 上关注公司。</p>
</div><p><strong>Forward-Looking Statements</strong></p>
<div class="lb-trans"><p><strong>前瞻性声明</strong></p>
</div><p>This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934 that involve risks and uncertainties. Statements containing words such as &#34;may,&#34; &#34;believe,&#34; &#34;anticipate,&#34; &#34;expect,&#34; &#34;intend,&#34; &#34;plan,&#34; &#34;project,&#34; &#34;will,&#34; &#34;projections,&#34; &#34;estimate,&#34; &#34;potentially&#34; or similar expressions constitute forward-looking statements. Such forward-looking statements are subject to significant risks and uncertainties and actual results may differ materially from the results anticipated in the forward-looking statements. These forward-looking statements are based upon Aethlon's current expectations and involve assumptions that may never materialize or may prove to be incorrect. Factors that may contribute to such differences include, without limitation, the Company's ability to raise additional capital, its ability to maintain its Nasdaq listing, to successfully complete development of the Hemopurifier; the Company's ability to successfully demonstrate the utility of the Hemopurifier in cancer and infectious diseases and in the transplant setting; the ability of the Hemopurifier to continue to show removal of platelet -derived EVs at a timepoint equivalent to a 4-hour HP treatment; the Company's ability to achieve and realize the anticipated benefits from its potential milestones; the Company's ability to submit applications to and obtain approval from the additional Ethics Committees in Australia and India, including on the timing expected by the Company; the Company's ability to initiate and continue its planned oncology clinical trials in Australia and India, including on the timing expected by the Company; the Company's ability to manage and successfully complete its clinical trials, if initiated; the Company's ability to successfully manufacture the Hemopurifier in sufficient quantities for its clinical trials, and other potential risks. The foregoing list of risks and uncertainties is illustrative, but is not exhaustive. Additional factors that could cause results to differ materially from those anticipated in forward-looking statements can be found under the caption &#34;Risk Factors&#34; in the Company's Annual Report on Form 10-K for the year ended March 31, 2025, and in the Company's other filings with the Securities and Exchange Commission, including its quarterly Reports on Form 10-Q. All forward-looking statements contained in this press release speak only as of the date on which they were made. Except as may be required by law, the Company does not intend, nor does it undertake any duty, to update this information to reflect future events or circumstances.</p>
<div class="lb-trans"><p>本新闻稿包含根据 1933 年证券法第 27A 条和 1934 年证券交易法第 21E 条的定义的前瞻性声明，这些声明涉及风险和不确定性。包含 “可能”、“相信”、“预期”、“期待”、“打算”、“计划”、“项目”、“将”、“预测”、“估计”、“潜在” 或类似表达的声明构成前瞻性声明。这些前瞻性声明受到重大风险和不确定性的影响，实际结果可能与前瞻性声明中预期的结果有重大差异。这些前瞻性声明基于 Aethlon 当前的预期，并涉及可能永远无法实现或可能被证明不正确的假设。可能导致这些差异的因素包括但不限于：公司筹集额外资本的能力、维持其纳斯达克上市的能力、成功完成 Hemopurifier 的开发的能力；公司成功展示 Hemopurifier 在癌症和传染病以及移植环境中的效用的能力；Hemopurifier 在相当于 4 小时 HP 治疗的时间点继续显示去除血小板衍生 EVs 的能力；公司实现和实现其潜在里程碑的预期收益的能力；公司向澳大利亚和印度的额外伦理委员会提交申请并获得批准的能力，包括公司预期的时间；公司在澳大利亚和印度启动和继续其计划中的肿瘤临床试验的能力，包括公司预期的时间；公司管理和成功完成其临床试验（如果启动）的能力；公司成功制造足够数量的 Hemopurifier 以供其临床试验的能力，以及其他潜在风险。上述风险和不确定性清单仅为示例，并非详尽无遗。可能导致结果与前瞻性声明中预期的结果有重大差异的其他因素可以在公司截至 2025 年 3 月 31 日的 10-K 表格年度报告中的 “风险因素” 标题下找到，以及公司向证券交易委员会提交的其他文件，包括其 10-Q 表格的季度报告。本新闻稿中包含的所有前瞻性声明仅在作出声明的日期有效。除非法律要求，否则公司不打算也不承担任何更新此信息以反映未来事件或情况的义务。</p>
</div><p><strong>Company Contacts:</strong> Jim Frakes</p>
<div class="lb-trans"><p><strong>公司联系人：</strong> Jim Frakes</p>
</div><p>Chief Executive Officer and Chief Financial Officer</p>
<div class="lb-trans"><p>首席执行官兼首席财务官</p>
</div><p>Aethlon Medical, Inc.</p>
<div class="lb-trans"><p>Aethlon Medical, Inc.</p>
</div><p>Jfrakes@aethlonmedical.com</p>
<div class="lb-trans"><p>Jfrakes@aethlonmedical.com</p>
</div><p><strong>Investor Contact:</strong> Susan Noonan</p>
<div class="lb-trans"><p><strong>投资者联系人：</strong> Susan Noonan</p>
</div><p>S.A. Noonan Communications, LLC</p>
<div class="lb-trans"><p>S.A. Noonan Communications, LLC</p>
</div><p>susan@sanoonan.com</p>
<div class="lb-trans"><p>susan@sanoonan.com</p>
</div><p>917-513-5303</p>
<div class="lb-trans"><p>917-513-5303</p>
</div><p>SOURCE Aethlon Medical, Inc.</p>
<div class="lb-trans"><p>来源：Aethlon Medical, Inc.</p>
</div>

Aethlon Medical Announces Pricing of a Private Placement and Warrant Inducement, Priced At-The-Market for Aggregate Gross Proceeds of $3.3 Million | AEMD Stock News

Aethlon Medical 宣布以市场价格定价进行私人配售和认股权证激励，总募集资金为 330 万美元 | AEMD 股票新闻